Significantly lower rates seen for all-cause mortality and unnatural-cause mortality, but not natural-cause mortality
Quit rate higher for ECs than nicotine replacement therapy; at six months, 62.8 percent in EC arm still using ECs
No serious injuries related to the medication mix-up have been reported
Models that enable primary care practitioners to diagnose and evaluate patients for treatment eligibility would have biggest impact on wait times
Reduction in incidence of positive PPD screening seen among women with prenatal depression undergoing elective C-section
Buprenorphine associated with lower risk for malformations, cardiac malformations, oral clefts, and clubfoot
In a recent study, severe QT prolongation occurred in 13.0 percent of quetiapine and 14.2 percent of haloperidol users
Both behavioral activation psychotherapy and antidepressant medication management reduce depressive symptoms by about 50 percent
No significant changes seen in new prescriptions for antidepressants, benzodiazepines, or buprenorphine for opioid use disorder
No association seen between cannabis use and nonmedical opioid use in those receiving pharmacotherapies for OUD